Mitophagy Drug TJ0113 Passes Long-Term Animal Safety Tests Ahead of Parkinson's Trial
GLP studies in rats and dogs found no target-organ toxicity or genotoxicity for TJ0113, a first-in-class mitophagy inducer now in Phase II Parkinson's testing.
Riepilogo
TJ0113 is an experimental small molecule that triggers mitophagy, the cell's process for clearing damaged mitochondria. It is now in a Phase II trial for Parkinson's disease. Researchers tested its safety in Sprague-Dawley rats (up to 26 weeks) and Beagle dogs (up to 39 weeks) under Good Laboratory Practice standards. They saw no treatment-related deaths and no target-organ toxicity. Heart tracings (ECG), blood chemistry and genotoxicity tests were normal or negative. Rats showed a small rise in relative kidney weight, but with no blood or tissue changes, so it was judged non-adverse. Drug exposure rose in proportion to dose and did not build up over time. The no-observed-adverse-effect levels were 100 mg/kg/day in rats and 60 mg/kg/day in dogs. These findings support continued human testing, though they cannot predict efficacy or human tolerability.
Riepilogo Dettagliato
Mitochondrial dysfunction is widely considered a driver of neurodegeneration, including Parkinson's disease. Mitophagy, the selective removal of damaged mitochondria, is therefore an attractive therapeutic target. Moving such drugs into people requires rigorous, regulatory-grade safety data.
This paper reports the Good Laboratory Practice (GLP) nonclinical safety package for TJ0113, a first-in-class small-molecule mitophagy inducer. It is being tested in a randomized, double-blind, placebo-controlled Phase II trial in Parkinson's disease (NCT06596005). Researchers ran single oral dose studies up to 1500 mg/kg and repeat-dose studies in Sprague-Dawley rats (15, 30, 100 mg/kg/day for 26 weeks) and Beagle dogs (6, 20, 60 mg/kg/day for 39 weeks). They assessed systemic toxicity, toxicokinetics, safety pharmacology including ECG, and a standard genotoxicity battery (Ames, chromosomal aberration, micronucleus).
No treatment-related deaths or target-organ toxicity occurred. Rats showed a modest increase in relative kidney weight, but with no biochemical or histopathological correlates, so it was considered non-adverse. Clinical pathology, ECG and dog urinalysis stayed within physiological limits, and all genotoxicity tests were negative. The drug was absorbed rapidly, with linear, dose-proportional exposure and no accumulation at the end of dosing. NOAELs were 100 mg/kg/day in rats and 60 mg/kg/day in dogs.
These results give a favorable nonclinical safety profile and support the ongoing clinical program, de-risking the human trials.
Caveats: this is an abstract-based summary. Animal safety does not guarantee human safety or efficacy. The study was authored in part by employees of the sponsoring company, and a senior author holds a related patent. Mitophagy-modulating drugs also carry theoretical long-term risks that animal studies may not capture.
Risultati Principali
- No treatment-related deaths or target-organ toxicity in rats (26 weeks) or dogs (39 weeks) under GLP conditions.
- NOAELs were 100 mg/kg/day in rats and 60 mg/kg/day in dogs, the highest doses tested.
- All genotoxicity tests (Ames, chromosomal aberration, micronucleus) were negative.
- Exposure was dose-proportional and linear, with rapid absorption and no accumulation at end of dosing.
- Rats had a modest relative kidney weight increase without biochemical or histological changes, judged non-adverse.
Metodologia
GLP-compliant single-dose (up to 1500 mg/kg oral) and repeat-dose toxicity studies were conducted in Sprague-Dawley rats (26 weeks) and Beagle dogs (39 weeks). Endpoints included clinical pathology, histopathology, toxicokinetics, ECG safety pharmacology, urinalysis, and an ICH S2(R1) genotoxicity battery.
Limitazioni dello Studio
Findings come from animal studies, and the abstract gives no human data or efficacy evidence; only the abstract was reviewed. The study has industry ties, including a company-affiliated author group and a patent held by a senior author, and independent replication is lacking.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: